Hematology

Hematology is the branch of internal medicine that studies blood—its cells, its plasma, and the proteins that make it clot—and the diseases that arise when any of these go wrong.

12 frameworks, from 150 to today · Internal Medicine · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Hematology is the branch of internal medicine that studies blood—its cells, its plasma, and the proteins that make it clot—and the diseases that arise when any of these go wrong1. Its practitioners diagnose and treat anemias, bleeding disorders such as hemophilia, abnormal clotting such as thrombosis, and cancers of the blood and bone marrow such as leukemia and lymphoma1. They also run blood banks and transfusion services, and they manage the most intensive treatments in medicine, including bone marrow transplantation and engineered immune cells. What is at stake is unusually direct: blood is the tissue that carries oxygen, defends against infection, and seals its own leaks, so when it fails, the whole body fails. The history of hematology is the story of how physicians learned to see what blood is made of, to count and classify its parts, to replace them, to understand the chemistry of clotting, and finally to attack and reprogram the cells that make them.

Ancient Humors and the Long Reign of Bloodletting

For more than two thousand years, the dominant theory of blood in European and Islamic medicine was humoralism, inherited from Greek physicians and systematized by Galen in the second century CE. Health was thought to depend on the balance of four bodily fluids—blood, phlegm, yellow bile, and black bile—and disease on their imbalance23. Blood was the warm, moist humor, and excess blood was treated by bloodletting, often by opening a vein. This was not a random practice: it followed from a coherent physiology, and it was taught in medical schools from Alexandria to Baghdad to Salerno. The theory's weakness was that it explained everything and predicted little; it could not distinguish one anemia from another or one bleeding disorder from another. Its long dominance meant that for centuries the observable properties of blood—its color, its tendency to clot in a cup, its separation into a dark clot and a pale serum—were interpreted within humoral categories rather than studied as objects in their own right.

Seeing the Cells: Morphology and the Microscope

The decisive break came with the microscope. In the seventeenth century, Antony van Leeuwenhoek described "red globules" in blood, and by the eighteenth and nineteenth centuries microscopists could see that blood contained several kinds of particles45. The key figure in morphological hematology—the study of blood cells by their appearance—was Paul Ehrlich, who in the 1870s and 1880s developed staining techniques that made different white blood cells distinguishable by the dyes they took up. Ehrlich's triacid and other stains revealed that leukocytes were not a single population but several lineages, and he named them by their staining behavior: neutrophils, eosinophils, basophils, lymphocytes. This mattered because it turned the blood into a readable tissue. A physician could now look at a stained smear and say not just "the blood is diseased" but which cell line was overproduced or missing.

The morphological tradition reached its height in the description of the anemias. In the nineteenth century, clinicians separated the pallor and weakness of anemia into distinct types by examining the size and color of red cells. The terms microcytic (small cells), macrocytic (large cells), and normocytic (normal-sized cells) became diagnostic categories, and the recognition that some anemias were caused by iron deficiency while others followed a dietary deficiency—pernicious anemia, later linked to vitamin B12—showed that morphology could point to cause. Sickle cell disease was described morphologically in 1910 by James Herrick, who saw the characteristic elongated cells in a dental student's blood; the underlying molecular defect would not be explained for another four decades.

Counting and Measuring: Quantitative Hematology

Morphology told you what cells looked like; quantitative hematology told you how many there were. Manual counting chambers, such as the hemocytometer, allowed nineteenth-century physicians to estimate cell concentrations, and the invention of the hemoglobinometer gave a measure of the blood's oxygen-carrying pigment. But the great transformation came in the mid-twentieth century with automated cell counting. The Coulter principle, developed by Wallace Coulter in the 1950s, measured cells by passing them through a small aperture and detecting changes in electrical impedance; the first commercial Coulter Counter appeared in 1956. Automated counters made complete blood counts fast, reproducible, and cheap, and they became standard in every hospital laboratory. Quantitative measures also reshaped diagnosis: the reticulocyte count (young red cells) distinguished whether anemia was due to underproduction or to loss and destruction, and the platelet count made bleeding risk assessable. The modern flow cytometer, developed from the 1960s onward, extended counting to individual cell types labeled with fluorescent antibodies, which became the basis of immunophenotypic hematology.

Replacing Blood: Transfusion and Blood Groups

The idea of replacing lost blood is old, but safe transfusion is a twentieth-century achievement. Early attempts at animal-to-human and human-to-human transfusion in the seventeenth and nineteenth centuries often failed, and the reasons were unknown. The critical discovery was made by Karl Landsteiner in 1900–1901, when he found that human sera agglutinated the red cells of some other humans in predictable patterns, defining the ABO blood groups67. This explained why some transfusions succeeded and others caused violent reactions, and it made matched transfusion possible. The first decades of the twentieth century saw the development of citrate anticoagulation, which allowed blood to be stored rather than transfused fresh, and the establishment of blood banks during the 1930s and especially during the Second World War. The Rh factor, discovered by Landsteiner and Alexander Wiener in 1940, explained hemolytic disease of the newborn and further refined matching. Transfusion science became a discipline of its own, concerned with compatibility, storage, fractionation of plasma into products such as albumin and clotting factor concentrates, and later with screening for infectious agents such as hepatitis and HIV.

The Chemistry of Clotting: Coagulation Cascade Theory

Bleeding disorders such as hemophilia had been recognized clinically for centuries—the classic description of an inherited bleeding tendency in a family is often credited to the tenth-century physician al-Zahrawi, and the modern name comes from the nineteenth century—but the mechanism of clotting was obscure. The twentieth century turned coagulation into a biochemical system. The recognition that plasma contained multiple distinct clotting factors, each a protein that activated the next in a chain, led to the cascade or waterfall model, proposed in the 1960s by researchers including Robert Macfarlane and Earl Davie and Ratnoff. In this model, a small initial trigger sets off a sequence of enzymatic activations, each amplifying the next, ending in the conversion of fibrinogen to fibrin, the mesh that forms the clot. The model explained why deficiency of a single factor—factor VIII in hemophilia A, factor IX in hemophilia B—caused bleeding, and it gave clinicians a map for laboratory testing: the prothrombin time and the partial thromboplastin time measure different branches of the cascade. It also made possible the development of anticoagulant drugs, from heparin to warfarin, and later to direct oral anticoagulants that target specific factors. The cascade model has since been refined by the cell-based model of coagulation, which emphasizes that clotting happens on the surfaces of cells rather than in a simple test tube, but the cascade remains the organizing framework taught to every student.

The Bone Marrow as the Source

If blood cells are produced somewhere, where? The bone marrow was identified as the site of blood formation in the nineteenth century, and bone marrow examination—aspiration of marrow fluid and biopsy of marrow tissue—became a diagnostic procedure in the early twentieth century. It allowed physicians to see the factory rather than only the product: to diagnose leukemia by the presence of malignant cells in the marrow, to identify aplastic anemia as marrow failure, and to stage lymphomas and other cancers that invade the marrow. The procedure was refined with special needles and staining methods, and it remains a core skill of hematology. Its logic—that diseases of blood are diseases of the marrow—underpins much of modern hematology.

Attacking the Malignant Cell: Chemotherapy and Transplantation

The mid-twentieth century brought the first effective treatments for blood cancers. The observation during the Second World War that nitrogen mustard damaged bone marrow and lymphoid tissue led to the use of alkylating agents in lymphoma, and in 1948 Sidney Farber reported that the antifolate aminopterin produced temporary remissions in childhood acute lymphoblastic leukemia. This was a landmark: it showed that a systemic chemical could kill leukemic cells. The 1950s and 1960s saw the development of combination chemotherapy, pioneered in childhood leukemia by investigators such as Emil Freireich and colleagues at the National Cancer Institute, who showed that combining drugs with different mechanisms could cure a disease that single agents only palliated. The principle—that cancer cells can be killed faster than normal cells recover, and that combinations reduce resistance—became central to oncology.

Cure by chemotherapy alone was limited by marrow toxicity. The next step was to replace the marrow. Hematopoietic stem cell transplantation—first performed successfully in the late 1960s by E. Donnall Thomas and colleagues, who used marrow from a matched sibling to treat leukemia—allowed patients to survive otherwise lethal doses of chemotherapy and radiation. The procedure required understanding of histocompatibility (the HLA system), graft-versus-host disease, and the biology of stem cells. It has since expanded to autologous transplantation (using the patient's own cells) and to reduced-intensity conditioning, and it remains the most intensive curative option for many hematologic malignancies.

Reading the Genome and the Cell Surface

From the 1960s onward, two new ways of seeing transformed hematology. Molecular and cytogenetic hematology began with the discovery of the Philadelphia chromosome in chronic myeloid leukemia by Peter Nowell and David Hungerford in 1960—a visibly shortened chromosome in leukemic cells8. This was the first consistent chromosomal abnormality linked to a human cancer, and it eventually led to the identification of the BCR-ABL fusion gene and to imatinib, the targeted drug that revolutionized treatment of that disease. Cytogenetics—the study of chromosomes—became a routine part of leukemia diagnosis, and molecular techniques such as PCR and later next-generation sequencing allowed detection of mutations that predict prognosis and guide therapy.

In parallel, immunophenotypic hematology used antibodies against cell-surface markers to classify cells. The development of monoclonal antibody technology in the 1970s and flow cytometry made it possible to identify a cell's lineage and stage of maturation with precision. The CD (cluster of differentiation) numbering system, established through international workshops from the 1980s, gave a common language for these markers. Immunophenotyping became essential for diagnosing leukemias and lymphomas, distinguishing them from benign conditions, and monitoring minimal residual disease after treatment.

Engineering the Immune System: Cellular Immunotherapy

The most recent turning point is cellular immunotherapy: using the patient's own immune cells as drugs. The idea that the immune system can attack cancer is old, but the tools to direct it are new. Chimeric antigen receptor (CAR) T-cell therapy, in which a patient's T cells are genetically engineered to recognize a specific marker on cancer cells, produced dramatic remissions in refractory acute lymphoblastic leukemia and some lymphomas in the 2010s9. The first CAR T-cell therapy was approved by the U.S. Food and Drug Administration in 2017 for certain pediatric and young adult leukemias. This approach descends directly from the immunophenotypic and molecular understanding of cell-surface markers and from transplantation biology, and it represents a shift from killing cells with chemicals to reprogramming the immune system to do it.

Hematology Today

Contemporary hematology combines all of these strands. Diagnosis rests on automated counts, morphological review of smears, flow cytometric immunophenotyping, cytogenetics, and molecular sequencing. Treatment ranges from transfusion and anticoagulation to targeted drugs, combination chemotherapy, transplantation, and engineered cell therapies. Blood banking remains a separate but closely allied discipline. The open questions are substantial: why do some patients relapse after CAR T-cell therapy, how can transplantation be made safer and more widely available, how do clonal blood disorders that arise with age (such as clonal hematopoiesis) progress to leukemia, and how can the successes in blood cancers be extended to solid tumors. The field's history is one of learning to see blood at ever finer scales—from the humors to the cell to the chromosome to the engineered receptor—and of turning each new way of seeing into a way of treating.

References

  1. Hematology (introduction, Scope), Wikipedia
  2. Menstruation and humoral medicine, Wikipedia
  3. Humorism (Origin), Wikipedia
  4. Complete blood count (History), Wikipedia
  5. Anemia (History), Wikipedia
  6. Blood type (History), Wikipedia
  7. ABO blood group system, Wikipedia
  8. Philadelphia chromosome (History), Wikipedia
  9. CAR T cell (introduction, History), Wikipedia

The frameworks of Hematology

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 150-1800

    Humorism

    What balance of bodily fluids keeps a person healthy?

    Fly to its tower in Nousfarer

  2. 1850-Present

    Quantitative hematology

    How many cells and how much hemoglobin are in the blood?

    Fly to its tower in Nousfarer

  3. 1870-Present

    Morphological hematology

    What do blood cells look like under the microscope?

    Fly to its tower in Nousfarer

  4. 1900-Present
  5. 1900-Present

    Transfusion medicine and blood banking

    How can one person's blood safely replace another's?

    Fly to its tower in Nousfarer

  6. 1940-Present

    Bone marrow examination

    What does the marrow show about a blood disease?

    Fly to its tower in Nousfarer

  7. 1955-Present
  8. 1960-Present

    Molecular and cytogenetic hematology

    What molecular defects cause blood diseases?

    Fly to its tower in Nousfarer

  9. 1964-Present
  10. 1968-Present
  11. 1975-Present

    Immunophenotyping

    What markers distinguish one blood cell from another?

    Fly to its tower in Nousfarer

  12. 2011-Present

    Cellular immunotherapy

    Can engineered immune cells kill cancer?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

HumorismQuantitative hematologyMorphological hematologyBone marrow as source paradigmTransfusion medicine and blood bankingBone marrow examinationCombination chemotherapyMolecular and cytogenetic hematologyCoagulationHematopoietic stem cell transplantati…ImmunophenotypingCellular immunotherapy

Beyond the field

Where Hematology's ideas came from in other fields, and what they led to there: the strongest 12 of 70 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Hematology is a planet in Nousfarer

Its city has a tower for each of these 12 frameworks. Land, walk in, and climb one concept at a time.

Land on Hematology

Related fields

Fields its ideas are linked to

More in Internal Medicine

See where Hematology sits on the Map of Human Knowledge